A Clinical Study to Investigate the Effect of an Investigational Drug on Electrocardiogram Intervals in Adults With Schizophrenia.

Schizophrenia Clinical Trial

Official title:

A Randomized, Single-dose, Crossover Study of the Effects of SEP-363856 on Electrocardiogram (ECG) Intervals in Subjects With Schizophrenia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04369391
• Other study ID #: SEP361-114
• Status: Completed
• Phase: Phase 1
• Start date: June 18, 2020
• Est. completion date: November 10, 2020

Study information

• Verified date: November 2020
• Source: Sunovion
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A clinical study to investigate the effect of an investigational drug in adults with schizophrenia by using Electrocardiogram (Picture of the electrical action of the heart). This study is accepting male and female participants between 18 years old -65 years old who have been diagnosed with schizophrenia. This study will be conducted in approximately 7 locations in the US. The study will last approximately 7 weeks.

Description:

This is a Phase 1, randomized, single-dose, active and placebo controlled, 3-period crossover study of the effect of SEP-363856 150 mg on electrocardiogram (ECG) intervals in subjects with schizophrenia. SEP-363856 and matching placebo will be utilized in a double-blind fashion. Moxifloxacin will be utilized as an active control in an open-label fashion. The primary analysis will be based on concentration-QTc modeling of the relationship between plasma concentrations of SEP-363856 or its metabolite SEP-363854 and change-from baseline QTc.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: November 10, 2020
• Est. primary completion date: November 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Male or female subject between 18 and 65 years of age, inclusive, at the time of informed consent
• Subject must give written informed consent and privacy authorization prior to participation in the study
• Subject meets DSM-5 criteria for a primary diagnosis of schizophrenia as established by clinical interview
• Subject must have a CGI S score = 4 at Screening
• Subject must have a PANSS total score = 80 at Screening
• Subject must have a score of = 4 on the following PANSS items at Screening:
• P7 (hostility)
• G8 (uncooperativeness)
• Subject must have normal to mild symptoms on all individual items of the SAS (< 2), AIMS (< 3) and BARS (< 3) at Screening
• Subject must be clinically stable for the past three months in the opinion of the Investigator
• Subject has been taking an antipsychotic for at least six weeks prior to Screening and has had no change in antipsychotic medication(s) for at least six weeks prior to Screening
• Subject is, in the opinion of the Investigator, generally healthy based on Screening medical history, physical examination, neurological examination, vital sign measurement, electrocardiogram and clinical laboratory values

Exclusion Criteria:

• Subject has a DSM 5 diagnosis or presence of symptoms consistent with a DSM 5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms are not the primary focus of treatment
• Subject tests positive for drugs of abuse or alcohol at Screening
• Subject is at significant risk of harming him/herself or others (passive or active) according to the Investigator's judgment.
• Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study
• Female subject who is pregnant or lactating
• Subject has any clinically significant abnormal laboratory value(s) at Screening as judged by the Investigator
• Subject has an abnormal, clinically significant 12-lead ECG at screening
• Subject has experienced significant blood loss (= 473 mL) or donated blood within 60 days prior to first dose of study drug; has donated plasma within 72 hours prior to the first dose of study drug or intends to donate plasma or blood or undergo elective surgery during study participation or within 60 days after the last study visit.
• Subject has an abnormal, clinically significant 12-lead ECG at screening
• Subject has a history of sick sinus syndrome, first, second, or third-degree AV block,myocardial infarction, NYHA Class II-IV heart failure, cardiomyopathy, pulmonary congestion, cardiac arrhythmia, prolonged QT interval, congenital long QT syndrome, family history of long QT, or moderate to severe hypokalemia

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• SEP363856 150 mg
SEP363856 tablet 150 mg
• Placebo
Placebo tablet
• moxifloxacin 400 mg
moxifloxacin tablet 400 mg

Locations

Country	Name	City	State
United States	Community Clinical Research Inc. Austin, TX 78754	Austin	Texas
United States	Research Centers of America, LLC	Hollywood	Florida
United States	Woodland International Research Group	Little Rock	Arkansas
United States	Collaborative Neuroscience Research, LLC	Long Beach	California
United States	Hassman Research Institute	Marlton	New Jersey
United States	California Neuropsychopharmacology Clinical Research Institute-LA, LLC (CNRI-LA, LLC)	Pico Rivera	California
United States	California Neuropsychopharmacology Clinical Research Institute-San Diego, LLC (CNRI-SD, LLC)	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Sunovion

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Placebo-adjusted change-from-baseline QTc interval (??QTc)		24 Hours
Secondary	Change from baseline in heart rate, QTcF, pulse rate, and QRS intervals (?HR, ?QTcF, ?PR, and ?QRS)		24 Hours
Secondary	If a substantial heart rate (HR) effect is observed: Change from baseline in QTcS, QTcI, and QTcP (?QTcS, ?QTcI, and ?QTcP)		24 Hours
Secondary	Placebo-adjusted change from baseline in heart rate, pulse rate, and QRS intervals (??HR, ??PR, and ??QRS)		24 Hours
Secondary	If a substantial heart rate (HR) effect is observed: Placebo-adjusted ?QTcS, and/or ?QTcI, and/or ?QTcP, and/or ?QTcF (??QTcS, ??QTcI, ??QTcP, ??QTcF) if not selected as the primary endpoint		24 Hours
Secondary	Categorical summary for QTcF, heart rate, pulse rate, and QRS intervals		24 Hours
Secondary	If a substantial heart rate (HR) effect is observed: Categorical summary for QTcS, QTcI, and QTcP		24 Hours
Secondary	Frequency of treatment-emergent changes of T-wave morphology and U-waves presence.		24 Hours